References: -
1. Yassin MA, Taher A, Mathews V, Hou HA, Shamsi T, Tuğlular TF, et al.
MERGE: A Multinational, Multicenter Observational Registry for
Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and
Algeria. Cancer Med. 2020 Jul;9(13):4512–26.
2. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM,
Guglielmelli P, et al. The 2016 WHO classification and diagnostic
criteria for myeloproliferative neoplasms: document summary and in-depth
discussion. Blood Cancer J. 2018 Feb 9;8(2):15.
3. Al-Mashdali AF, Kashgary WR, Yassin MA. Ruxolitinib (a JAK2
inhibitor) as an emerging therapy for refractory pruritis in a patient
with low-risk polycythemia vera: A case report. Medicine (Baltimore).
2021 Nov 5;100(44):e27722.
4. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment
algorithm 2018. Blood Cancer J. 2018 Jan 10;8(1):3.
5. Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated
pruritus and its management. Eur J Clin Invest. 2010 Sep;40(9):828–34.
6. Lelonek E, Matusiak Ł, Wróbel T, Szepietowski JC. Aquagenic Pruritus
in Polycythemia Vera: Clinical Characteristics. Acta Derm Venereol. 2018
Apr 27;98(5):496–500.
7. Gangat N, Strand JJ, Lasho TL, Li CY, Pardanani A, Tefferi A.
Pruritus in polycythemia vera is associated with a lower risk of
arterial thrombosis. Am J Hematol. 2008 Jun;83(6):451–3.
8. Silver RT. Long-term effects of the treatment of polycythemia vera
with recombinant interferon-alpha. Cancer. 2006 Aug 1;107(3):451–8.
9. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E,
et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor,
in patients with advanced polycythemia vera who are refractory or
intolerant to hydroxyurea. Cancer. 2014 Feb 15;120(4):513–20.
10. Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, et al.
The efficacy and safety of continued hydroxycarbamide therapy versus
switching to ruxolitinib in patients with polycythaemia vera: a
randomized, double-blind, double-dummy, symptom study (RELIEF). Br J
Haematol. 2017 Jan;176(1):76–85.
11. Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J,
et al. Ruxolitinib for the treatment of inadequately controlled
polycythemia vera without splenomegaly: 80-week follow-up from the
RESPONSE-2 trial. Ann Hematol. 2018 Sep;97(9):1591–600.
12. Yassin MA, Al-Dewik NI, ElAyoubi H, Cassinat B. Efficacy and safety
of pegelated interferon alpha2a once monthly compared to once weekly
dose in patients with essential thrombocythemia. Blood. 2013 Nov
15;122(21):4054.
13. Taher A, Yassin MA, Xiao Z, Hou HA, Tuglular T, Mathews V, Rippin G,
Sadek I, Siddiqui A, Wong RS. Impact of myeloproliferative neoplasms
(MPNs) on health-related quality of life (HRQOL) and medical resource
utilization: results from the MERGE registry. Blood. 2018 Nov
29;132:4311.
14. Yassin MA, Nehmeh SA, Nashwan AJ, Kohla SA, Mohamed SF, Ismail OM,
Al Sabbagh A, Ibrahim F, Soliman DS, Szabados L, Fayad H. A study of
18F-FLT positron emission tomography/computed tomography imaging in
cases of prefibrotic/early primary myelofibrosis and essential
thrombocythemia. Medicine. 2020 Nov 6;99(45).
15. Sasi S, Mohamed M, Chitrambika P, Yassin MA. Myasthenia Gravis and
Myeloproliferative Neoplasms–Mere Association or Paraneoplastic
Neurologic Syndrome: A Mini-Review. Acta Bio Medica: Atenei Parmensis.
2022;92(6).
16. Ali EA, Abu-Tineh M, Hailan Y, Al-maharmeh QA, Maat ZO, Babiker AM,
Ali B, Ismail AS, Yassin MA. The Outcome of Fatherhood in Patients with
Philadelphia Negative Myeloproliferative Neoplasms, a Single Institution
Experience “. Blood. 2021 Nov 23;138:4625.
16. Ali EA, Abu-Tineh M, Hailan Y, Al-maharmeh QA, Maat ZO, Babiker AM,
Ali B, Ismail AS, Yassin MA. The Outcome of Fatherhood in Patients with
Philadelphia Negative Myeloproliferative Neoplasms, a Single Institution
Experience “. Blood. 2021 Nov 23;138:4625.